Role of androgen deprivation therapy for node-positive prostate cancer

Journal of Clinical Oncology

Volumn 27, Issue 1, 2009, Pages 100-105

  Wong, Yu Ning ^a   Freedland, Stephen ^a   Egleston, Brian ^a   Hitdes, Gary ^a   Schwartz, J Sanford ^a   Armstrong, Katrina ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY ANALYSIS;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; HUMANS; LYMPHATIC METASTASIS; MALE; PROSTATIC NEOPLASMS; SEER PROGRAM;

EID: 58149347802     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.2042     Document Type: Article

References (23)

1. Adib R S, Anderson J B, Ashken M H, et al: Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council trial. Br J Urol 79: 235-246, 1997
2. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295-300, 1997
3. Messing E M, Manola J, Yao J, et al: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7: 472-479, 2006
4. Messing E M, Manola J, Sarosdy M, et al: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341: 1781-1788, 1999
5. Pound C R, Partin A W, Eisenberger M A, et al: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591-1597, 1999
6. Morote J, Morin J P, Orsola A, et al: Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology 69: 500-504, 2007
7. Keating N L, O'Malley A J, Smith M R: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448-4456, 2006
8. Sharifi N, Gulley J L, Dahut W L: Androgen deprivation therapy for prostate cancer. JAMA 294: 238-244, 2005
9. Potosky A L, Harlan L C, Stanford J L, et al: Prostate cancer practice patterns and quality of life: The prostate cancer outcomes study. J Natl Cancer Inst 91: 1719-1724, 1999
10. Elixhauser ASC, Harris D R, Coffey R M: Co-morbidity measures for use with administrative data. Med Care 36: 8-27, 1998
11. Fine J, Gray R: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94: 496-509, 1999
12. Harrell F: Regression Modeling Strategies. New York, NY, Springer, 2001
13. Schröder F H K K, Fossa S D, Hoekstra W, Karthaus P P, Debois M, Collette L: Early versus delayed endocrine treatment of pN1-3 MO prostate cancer without local treatment of the primary tumor: Results of European Organisation for the Research and Treatment of Cancer 30846-A phase III study. J Urol 172: 923-927, 2004
14. Loblaw D A, Virgo K S, Nam R, et al: Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 25: 1596-1605, 2007
15. Ryan C J E E, Cowan J, Carroll P R: Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation. Cancer 110: 81-86, 2007
16. Freedland S J, Humphreys E B, Mangold L A, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294: 433-439, 2005
17. Elting L S, Cooksley C, Bekele B N, et al: Generalizability of cancer clinical trial results: Prognostic differences between participants and nonparticipants. Cancer 106: 2452-2458, 2006
18. Kawakami J, Meng M V, Sadetsky N, et al: Changing Patterns of Pelvic Lymphadenectomy for Prostate Cancer: Results From CaPSURE. J Urol 176: 1382-1386, 2006
19. Swanson G, Thompson I M, Basler, J: Current status of lymph node-positive prostate cancer. Cancer 107: 439-450, 2006
20. Hanks G E, Pajak T F, Porter A, et al: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 9202. J Clin Oncol 21: 3972-3978, 2003
21. Aus G, Abrahamsson P A, Ahlgren G, Hugosson J, Lundberg S, Schain M, Schelin S, Pedersen K: Three-month neoadjuvant hormonal therapy before radical prostatectomy: A 7-year follow-up of a randomized controlled trial. BJU International 90: 561-566, 2002
22. Soloway M S, Pareek K, Sharifi R, et al: Neo adjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167:112-116, 2002
23. Ryan C J, Small E J: Early versus delayed androgen deprivation for prostate cancer: New fuel for an old debate. J Clin Oncol 23: 8225-8231, 2005